Comparative Pharmacology
Head-to-head clinical analysis: IOPAMIDOL 370 versus OXILAN 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IOPAMIDOL 370 versus OXILAN 300.
IOPAMIDOL-370 vs OXILAN-300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iopamidol is a nonionic, water-soluble, iodinated radiographic contrast agent that attenuates X-rays, thereby enhancing vascular and tissue contrast during imaging procedures. Its mechanism is physical rather than pharmacological, based on iodine content and osmolality.
Iodinated contrast agent that attenuates X-rays and enhances vascular and tissue visualization during imaging procedures.
1-2 mL/kg (370 mg iodine/mL) IV up to a maximum of 150 mL per procedure for contrast-enhanced CT; for angiography, dose varies by procedure.
Intravenous: 1-2 mL/kg (300 mg iodine/mL) for contrast imaging; maximum dose 2 mL/kg per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5-2.5 hours) in patients with normal renal function. Prolonged to 10-70 hours in patients with renal impairment, necessitating dose adjustment or avoidance.
Terminal half-life: 1.5–2.5 hours (normal renal function); prolonged in renal impairment (up to 30 hours in severe impairment).
Primarily renal; >90% of administered dose excreted unchanged in urine via glomerular filtration within 24-48 hours. Less than 1% excreted in feces or bile.
Renal elimination: 100% unchanged via glomerular filtration; biliary/fecal excretion negligible (<1%).
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent